Skip to main content

Mary Rozenman


Mary Rozenman has 20 years of scientific expertise, company building and transactions leadership in the biotechnology industry. Since 2019, she has been CFO/CBO of insitro, a company applying machine learning and generative AI to data at scale to transform drug discovery and development. At insitro, she leads strategic and operational functions, including finance and accounting, strategy, corporate development, investor relations and corporate communications. Mary serves as an independent director on the board of Tessera Therapeutics, a company pioneering gene writing. Mary has been recognized on Endpoints’ top 20 under 40 in biopharma list and the Business Insider top 30 under 40 transforming healthcare. Prior to insitro, she was SVP of corporate development and strategy at Aimmune Therapeutics (acquired for $2.6B), where she was a founding team member and established collaborations with Regeneron, Sanofi and Nestlé. Mary has raised over $1B in capital through a range of private and public transactions, including co-leading Aimmune’s 2015 IPO. Earlier in her career, Mary was a biotechnology investor at Longitude Capital and a junior partner at McKinsey focused on pharmaceuticals and corporate finance. Mary holds a Ph.D. in organic chemistry and chemical biology from Harvard University and a B.A. in biochemistry and Russian literature from Columbia University. Her academic work has been published in premier journals including Nature and she is a named inventor on several patents.